glamor
发表于 2025-3-26 22:39:34
http://reply.papertrans.cn/19/1879/187804/187804_31.png
充足
发表于 2025-3-27 01:32:45
http://reply.papertrans.cn/19/1879/187804/187804_32.png
形容词词尾
发表于 2025-3-27 08:30:33
http://reply.papertrans.cn/19/1879/187804/187804_33.png
闪光东本
发表于 2025-3-27 10:04:15
Assays for Gene AmplificationSince the approval of trastuzumab for the treatment of .-positive breast cancer (.), there has been an active debate as to the reproducibility and validity of the FDA-approved assays that detect . abnormalities in the tumor tissue. In this chapter, various clinical assays are compared focusing on practical issues.
arabesque
发表于 2025-3-27 16:23:20
http://reply.papertrans.cn/19/1879/187804/187804_35.png
FLING
发表于 2025-3-27 18:12:58
Biomarkers in Breast Cancer978-1-59259-915-8Series ISSN 2196-9906 Series E-ISSN 2196-9914
得意人
发表于 2025-3-27 22:54:50
Guidelines for the Design of Clinical Studies for the Development and Validation of Therapeutically tic marker studies for breast cancer is inconsistent, and few such markers have been adopted for widespread use in clinical practice. This is problematic, as many patients are over-treated and many others are treated ineffectively. The deficiencies in clinical development of biomarkers may become mo
installment
发表于 2025-3-28 03:23:58
http://reply.papertrans.cn/19/1879/187804/187804_38.png
Gene408
发表于 2025-3-28 09:32:50
http://reply.papertrans.cn/19/1879/187804/187804_39.png
古代
发表于 2025-3-28 13:58:56
Cell Kinetics in the past years many laboratories have set up and compared different approaches to measure the proliferation of tumor cells for clinical use. Although available results suggest that the majority of proliferation indices may help clinicians in treatment decision making, their clinical usefulness i